OncLive TV

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the impact of next-generation sequencing (NGS) in acute myeloid leukemia (AML).

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, compares the costs and outcomes of chemotherapy in the United States and Canada for patients with colorectal cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, provides a global perspective on the integration of biosimilars into cancer care.

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses BCL-2 inhibition in acute myeloid leukemia (AML).

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses radiotherapy in breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses updates in neoadjuvant and adjuvant therapy for patients with colorectal cancer.

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses pain management in patients with ovarian cancer.

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses approaching palliative care for children with cancer.

Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.